Skip to content
StackItSmart
BHuman cohort / observational

Lion's Mane Extract

Hericium erinaceus

Lion's Mane (Hericium erinaceus) is an edible/medicinal mushroom sold as a nootropic supplement (fruiting-body powder/extract or erinacine-enriched mycelium). It is marketed for memory, focus, and mood. Human evidence is thin and low-quality — a handful of small, mostly Japanese/industry-linked randomized trials (typically 15-50 subjects) show modest, inconsistent, and often transient cognitive/mood signals, with no large or long-term data. It is not a proven treatment for dementia, ALS, or depression. The main documented human danger is allergy: at least one anaphylaxis case has been reported after consuming fresh Lion's Mane, and mushroom material can cause contact dermatitis and respiratory hypersensitivity. Trials reported no adverse changes on routine bloodwork, but there is no robust long-term safety, hepatic, cardiac, or hormonal monitoring data. Because supplements are unregulated, product identity, dose, and contamination are real uncertainties. Anyone with mushroom allergy should avoid it, and anyone using it for a serious neurological or psychiatric condition should do so only under a clinician's care rather than in place of evidence-based treatment.

Clinical readoutPED-adjacent · nootropic
Hepatic strainNone
CardiovascularNone
HPTA suppressionNone
Half-life
Not established i…
Route
Oral
Evidence
B
Active
Unknown in humans
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not established in humans. No validated human pharmacokinetic data exist for hericenones or erinacines; human half-life is unknown.
Pharmacology

Mechanism of action

The proposed active compounds are hericenones (concentrated in the fruiting body) and erinacines (concentrated in cultured mycelium). In preclinical (cell and rodent) models these low-molecular-weight compounds stimulate nerve growth factor (NGF) synthesis and are associated with neurite outgrowth, modulation of neurotrophins/BDNF, anti-inflammatory and antioxidant activity, reduced neuronal apoptosis, and neuroprotection; erinacine A has demonstrated central nervous system activity in rats and appears able to cross the blood-brain barrier in animals. Whether these NGF/neurotrophic mechanisms operate at achievable doses in the human brain is unproven, and at least one human trial found mood/anxiety benefit that the authors suspected occurred via a mechanism distinct from NGF enhancement. Mechanistic claims are therefore largely preclinical extrapolation.
Kinetics

Pharmacokinetics

Half-life

Not established in humans. No validated human pharmacokinetic data exist for hericenones or erinacines; human half-life is unknown.

Active duration

Unknown in humans. Human trials dosed 1-3 times daily (chronic) or measured acute cognitive effects at 60-120 minutes post-dose, implying rapid but short-lived acute activity; cognitive gains in a mild-cognitive-impairment trial reversed within 4 weeks of stopping, suggesting no durable carry-over.

Route

Oral (capsules, tablets, or powder of dried fruiting body, standardized extracts, or erinacine-enriched mycelium).

Metabolism & clearance

Not characterized in humans. No adequate human absorption, distribution, metabolism, or clearance data; animal data suggest central penetration of erinacine A but cannot be extrapolated to humans. This information is inadequate for any washout/monitoring calculation.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • In older adults with mild cognitive impairment, a small 16-week RCT reported improved cognitive-scale scores (Hasegawa Dementia Scale-Revised) during intake, which declined again after discontinuation.
  • A 12-week RCT in older adults reported improvement on the Mini-Mental State Examination but not on other cognitive tests used.
  • A 4-week RCT in menopausal women reported reduced depression and anxiety scores (CES-D, Indefinite Complaints Index).
  • Small pilot/acute RCTs in healthy young adults reported inconsistent, task-specific effects (e.g., faster Stroop or reaction-time performance, a pegboard improvement, a non-significant trend toward reduced subjective stress) rather than broad cognitive enhancement.
  • One acute crossover RCT of a fruiting-body extract found no significant overall effect on global cognition or mood, with benefit limited to a single motor-dexterity task.
  • Overall: effects are modest, inconsistent across studies and endpoints, often transient, and derived from small samples; Lion's Mane is not a demonstrated therapy for any neurological or psychiatric disease.
Safety

Adverse effects by system

Cardiovascular

No cardiovascular adverse effects have been established in humans; the small trials did not report cardiac events, but none were designed or powered to detect cardiovascular harm, so absence of reports is not evidence of safety.

Hepatic

No human hepatotoxicity signal has been reported; trials that checked routine laboratory tests reported no adverse changes, but liver enzymes were not systematically or long-term monitored, so hepatic safety is not firmly established.

Endocrine / HPTA

No human data. Lion's Mane is not a hormonal agent and there is no evidence it affects testosterone, gonadotropins, or the hypothalamic-pituitary-gonadal axis; endocrine effects have not been studied.

Reproductive

No human reproductive, pregnancy, or lactation safety data exist; effects on fertility, pregnancy, or breastfeeding are unknown and it should be avoided in these settings absent data.

Neuropsychiatric

No consistent psychiatric adverse effects reported; trials examined mood as a benefit (reduced depression/anxiety scores) rather than harm. No withdrawal syndrome described, but psychiatric safety in people with existing mental-health conditions is unstudied.

Renal

No known renal adverse effects and no dedicated human renal safety data; not studied.

Hematologic

No established hematologic adverse effects in humans; trials reported no adverse laboratory changes, but effects on coagulation and blood counts have not been rigorously studied.

Dermatologic

Allergic/hypersensitivity reactions are the best-documented human risk. Mushroom material can cause contact dermatitis, and Hericium erinaceus is capable of provoking hypersensitivity; skin reactions can be part of a systemic allergic response.

Recovery

HPTA suppression & recovery

Suppression: None expected / no evidence of HPTA involvement

Lion's Mane is a non-hormonal nootropic mushroom with no evidence of hypothalamic-pituitary-gonadal axis suppression, so no SERM-based restart or recovery protocol is applicable or indicated. Post-cycle SERM therapy is neither relevant nor recommended here. Anyone with concerns about hormonal status or who is combining supplements with anabolic or hormonal agents should consult a qualified endocrinologist rather than self-managing; this monograph does not endorse any SERM use.

Bloodwork & vitals

Monitoring

Recommended labs & checks
No condition-specific labs are validated for Lion's Mane; for anyone using it regularly a clinician may obtain baseline and periodic complete blood count, liver function tests (AST/ALT/bilirubin), and renal function (creatinine/eGFR) as general supplement-safety monitoringBaseline documentation of any mushroom allergy history before first use

Cadence: If used chronically, discuss with a clinician; a reasonable general approach is baseline bloodwork and re-check at roughly 8-12 weeks and then periodically, though no evidence-based schedule exists. Discontinue immediately and seek care for any allergic reaction.

Warning signs — seek care
  • Signs of anaphylaxis or severe allergy: hives, facial/lip/tongue/throat swelling, difficulty breathing, wheeze, dizziness or collapse — call emergency services immediately
  • Skin rash, itching, or contact dermatitis
  • New respiratory symptoms (cough, shortness of breath) suggesting respiratory hypersensitivity
  • Any new jaundice, dark urine, right-upper-quadrant pain, or unexplained fatigue (prompt liver evaluation)
  • Lack of benefit or worsening of the underlying condition it is being taken for — do not delay proven medical care
Do not use if

Contraindications

  • Known allergy or hypersensitivity to Lion's Mane or other mushrooms/fungi (risk of anaphylaxis).
  • Pregnancy and breastfeeding (no safety data).
  • History of asthma or respiratory hypersensitivity to fungal/mushroom material.
  • Do not use as a substitute for evidence-based treatment of dementia, ALS, depression, or any diagnosed neurological/psychiatric disease.
  • Caution and clinician involvement if combining with other supplements or medications given unknown interaction and metabolism profile.
  • Scheduled surgery or bleeding disorders: use caution and disclose to the clinician, since coagulation effects are unstudied.
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • If you have any mushroom or fungal allergy, do not take Lion's Mane — anaphylaxis has been reported after fresh consumption.
  • Have a plan for allergic reactions: stop immediately and seek emergency care for hives, swelling, wheeze, or breathing difficulty; carry emergency medication only per your own clinician's advice.
  • Do not use Lion's Mane in place of proven treatment for dementia, ALS, depression, or any diagnosed condition; involve your physician if using it for a health concern.
  • Treat it as an unproven supplement: benefits in trials were small, inconsistent, and often transient, and stopping reversed gains in one study.
  • Because supplements are unregulated, product content, dose, and purity vary; a third-party-tested product reduces (but does not eliminate) contamination/identity uncertainty.
  • Consider baseline and periodic bloodwork (CBC, liver and kidney function) with a clinician if using it long-term, since long-term human safety is unknown.
  • Avoid during pregnancy and breastfeeding and disclose use before surgery, given absent safety and interaction data.
  • Stop and consult a clinician if you develop rash, new respiratory symptoms, jaundice, or any unexplained symptom.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    A 16-week double-blind placebo-controlled RCT in adults with mild cognitive impairment found improved cognitive-scale (HDS-R) scores during intake that declined after discontinuation, with no adverse effects on laboratory tests.

    RCTPMID 18844328 ↗

  2. 02

    A 12-week randomized, double-blind, placebo-controlled multicenter trial of H. erinaceus fruiting body in older adults reported improved Mini-Mental State Examination scores but not other cognitive tests, and described oral intake as safe.

    RCTPMID 31413233 ↗

  3. 03

    A 4-week double-blind RCT in 30 menopausal women reported reduced depression and anxiety indices (CES-D and Indefinite Complaints Index), with authors suggesting a mechanism distinct from NGF enhancement.

    RCTPMID 20834180 ↗

  4. 04

    A double-blind placebo-controlled pilot RCT in 41 healthy young adults (1.8 g/day) found faster Stroop performance after a single acute dose and only a non-significant trend toward reduced subjective stress after 28 days, with null and limited negative findings and a small sample cautioning interpretation.

    RCTPMID 38004235 ↗

  5. 05

    An acute randomized, double-blind, placebo-controlled crossover trial (1 g Lion's Mane) reported improved working memory, complex attention, and reaction time over 2 hours.

    RCTPMID 38140277 ↗

  6. 06

    An acute randomized, double-blind, placebo-controlled crossover trial of 3 g of a 10:1 fruiting-body extract in healthy young adults found no significant overall improvement in cognition or mood, with benefit limited to a single dexterity (pegboard) task.

    RCTDOI 10.3389/fnut.2025.1405796 ↗

  7. 07

    A review of Lion's Mane for ALS notes that human data are very limited, that only one small MCI trial has shown temporary cognitive improvement (not yet replicated), that it appears safe and inexpensive, and that one anaphylactic case was reported after a patient consumed fresh Lion's Mane mushroom.

    ReviewPMID 38141002 ↗

  8. 08

    Proposed neurotrophic mechanism: hericenones and erinacines stimulate NGF synthesis, promote neurite outgrowth, and exert neuroprotective, anti-inflammatory and antioxidant effects, with erinacine A showing CNS activity and blood-brain-barrier penetration in rodents (preclinical).

    ReviewPMID 37958943 ↗

  9. 09

    Erinacine-enriched mycelium mechanisms and neurohealth effects (ischemic stroke, Parkinson's, Alzheimer's, depression models) are supported only by preclinical studies that are difficult to extrapolate to clinical situations; erinacine A is the compound with confirmed CNS pharmacological action in rats.

    PreclinicalPMID 29951133 ↗

  10. 10

    Narrative review of Alzheimer's disease found only three clinical studies alongside preclinical work, with therapeutic potential but a need for standardized parameters, mechanism elucidation, and safety confirmation.

    ReviewPMID 35892581 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice